血清CEA、NSE及CYFRA21-1联合检测对肺癌的诊断价值

为探讨血清CEA、NSE及CYFRA21-1对不同组织类型肺癌的诊断价值,对95例肺癌患者（其中鳞癌38例,腺癌41例,小细胞肺癌16例）和45例肺部良性病变患者（对照组）,用电化学发光免疫分析法检测血清CEA、NSE及CYFRA 21-1。结果表明,CEA在腺癌中阳性率最高（52.2%）,NSE在小细胞肺癌的阳性率为69.7%,CYFRA21-1在鳞癌及腺癌的阳性率分别为57.3%、46.7%。三项联合检测在鳞癌、腺癌及小细胞肺癌中的阳性率分别为71.3%、89.9%及72.8%。CEA、NSE及CYFRA21-1在不同的肺癌病理类型有不同的表达,单项标志物对肿瘤的诊断价值有限,而且某些良性疾病也可以升高。三项标志物联合检测可提高肺癌诊断的敏感性和特异性。

Diagnostic Value of Combined Detection of Serum CEA,NSE and CYFRA 21-1 in Patients with Lung Cancer

To evaluate the diagnostic value of CEA,NSE and CYFRA 21-1 in lung cancer with different histological types,the serum levels of CEA,NSE and CYFRA 21-1 were analyzed by ECLIA in 95 patients with pathologically confirmed lung cancer including 38 patients with squamous cell carcinoma,41 with adenocarcinoma,16 with small cell lung cancer,and 45 patients with benign diseases.The results showed that the highest positive rates among different pathological cell types was CEA in adenocarcinoma(52.2%),NSE in small ce...